GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (STU:7AL) » Definitions » Capex-to-Revenue

Alligator Bioscience AB (STU:7AL) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alligator Bioscience AB Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Alligator Bioscience AB's Capital Expenditure for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €0.62 Mil.

Hence, Alligator Bioscience AB's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Alligator Bioscience AB Capex-to-Revenue Historical Data

The historical data trend for Alligator Bioscience AB's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Capex-to-Revenue Chart

Alligator Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.02 - 0.01 0.04

Alligator Bioscience AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.11 - - -

Competitive Comparison of Alligator Bioscience AB's Capex-to-Revenue

For the Biotechnology subindustry, Alligator Bioscience AB's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Capex-to-Revenue falls into.



Alligator Bioscience AB Capex-to-Revenue Calculation

Alligator Bioscience AB's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.22) / 5.195
=0.04

Alligator Bioscience AB's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.617
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alligator Bioscience AB  (STU:7AL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Alligator Bioscience AB Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alligator Bioscience AB (STU:7AL) Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a research-based biotechnology company that develops immune activating antibody drugs for tumor-directed immunotherapy. It is engaged in the development of immunotherapies for the treatment of cancer Its products are ADC-1013, ATOR-1015, and ATOR-1016.

Alligator Bioscience AB (STU:7AL) Headlines

No Headlines